Investor Relations

Press Releases

Date Title and Summary
July 22, 2021
TEL AVIV, Israel , July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ( Nasdaq: VBLT ) today announced the planned elevation of Marc Kozin as chairman of the company’s board of directors. Bennett Shapiro , M.D., has stepped down from his chairman role but remains on VBL’s board.
July 8, 2021
TEL AVIV, Israel , July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021 . Professor Ruth Arnon has stepped down from her role as a member of VBL’s Board of Directors,
June 15, 2021
TEL AVIV, Israel , June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was notified by the U.S Food and Drug
June 3, 2021
Second primary endpoint added following discussion with the U.S. Food and Drug Administration Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA   for potential full FDA approval PFS endpoint readout expected in 2022; BLA submission could be
May 20, 2021
TEL AVIV, Israel , May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual
May 11, 2021
Conference Call and Webcast at 8:30 a.m. EDT Today OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC review expected 3Q21 Closed public offering, raising
May 4, 2021
TEL AVIV, Israel , May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron , Chief Financial
April 14, 2021
TEL AVIV, Israel , April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the closing of its underwritten public offering of 6,901,790 ordinary shares, and, to certain investors in lieu thereof, pre-funded warrants to
April 9, 2021
TEL AVIV, Israel , April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced the pricing of an underwritten public offering of 5,150,265 ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase
April 8, 2021
TEL AVIV, Israel , April 08, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT), today announced that it intends to offer and sell ordinary shares and, to certain investors in lieu thereof, pre-funded warrants to purchase ordinary shares in an
Displaying 1 - 10 of 242